# Dr. Reddy's Laboratories Limited, India trials: 224 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 224 trials with Dr. Reddy's Laboratories Limited, India as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Dr. Reddy's Laboratories Limited, India: 224 rows for $11.20, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/dr-reddys-laboratories-limited-india

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 224
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 224, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 4, 2026 | NCT07744828 | A Study to Evaluate Pharmacokinetics of DRL\_AB in Healthy Male Participants | Dr. Reddy's Laboratories Limited, India | Phase 1 | Not yet recruiting | Healthy Volunteers | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744828) |
| November 13, 2023 | NCT06126042 | Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route | Dr. Reddy's Laboratories Limited, India | Phase 1 | Unknown | Rheumatoid Arthritis | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06126042) |
| November 23, 2020 | NCT04640233 | Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome... | Dr. Reddy's Laboratories Limited, India | Phase 2/3 | Unknown | COVID-19 Prevention | 1,600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04640233) |
| August 27, 2020 | NCT04529499 | Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients | Dr. Reddy's Laboratories Limited, India | Phase 3 | Terminated | Covid19 | 353 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04529499) |
| February 13, 2020 | NCT04268771 | A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products | Dr. Reddy's Laboratories Limited, India | Phase 3 | Completed | Rheumatoid Arthritis | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04268771) |
| June 5, 2019 | NCT03976102 | Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL\_RI) With MabThera® in LTB Follicular Lymphoma | Dr. Reddy's Laboratories Limited, India | Phase 3 | Completed | Follicular Lymphoma | 317 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03976102) |
| October 15, 2018 | NCT03706300 | Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg Under Fasting Conditions | Dr. Reddy's Laboratories Limited, India | Phase 1 | Completed | Healthy | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03706300) |
| October 11, 2018 | NCT03702855 | Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fed Conditions | Dr. Reddy's Laboratories Limited, India | Phase 1 | Completed | Healthy | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03702855) |
| October 4, 2018 | NCT03696329 | Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fasting Conditions | Dr. Reddy's Laboratories Limited, India | Phase 1 | Completed | Healthy | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03696329) |
| July 26, 2018 | NCT03599193 | A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris | Dr. Reddy's Laboratories Limited, India | Phase 2 | Completed | Acne Vulgaris | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03599193) |
| June 13, 2018 | NCT03554772 | Efficacy, Tolerability, Safety, and Pharmacokinetic Study of DFN-15 | Dr. Reddy's Laboratories Limited, India | Phase 2 | Completed | Acute Pain | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03554772) |
| February 5, 2018 | NCT03421197 | A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) | Dr. Reddy's Laboratories Limited, India | Phase 2 | Completed | Psoriasis | 426 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03421197) |
| November 14, 2017 | NCT03341910 | A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical... | Dr. Reddy's Laboratories Limited, India | Phase 2 | Completed | Acne Vulgaris | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03341910) |
| November 14, 2017 | NCT03340961 | A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules | Dr. Reddy's Laboratories Limited, India | Phase 2 | Completed | Rosacea | 205 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03340961) |
| September 25, 2017 | NCT03292640 | A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks | Dr. Reddy's Laboratories Limited, India | Phase 3 | Completed | Acne Vulgaris | 547 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03292640) |
| September 21, 2017 | NCT03290027 | A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris | Dr. Reddy's Laboratories Limited, India | Phase 3 | Completed | Acne Vulgaris | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03290027) |
| September 14, 2017 | NCT03282838 | Study on the Pharmacokinetics (PK) of DFN-15 vs Comparator and Food-effect on DFN-15 PK in Healthy Adult Subjects | Dr. Reddy's Laboratories Limited, India | Phase 1 | Completed | Migraine | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03282838) |
| May 19, 2017 | NCT03160807 | Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections | Dr. Reddy's Laboratories Limited, India | Phase 4 | Unknown | Urinary Tract Infection | 214 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03160807) |
| April 17, 2017 | NCT03116698 | A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week... | Dr. Reddy's Laboratories Limited, India | Phase 2/3 | Completed | Actinic Keratosis (AK) | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03116698) |
| February 14, 2017 | NCT03051685 | Bioavailability of DFN-15 at 3 Different Doses vs. Comparator and to Determine Dose-proportionality of DFN-15 in Fasting Healthy Adults | Dr. Reddy's Laboratories Limited, India | Phase 1 | Completed | Healthy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03051685) |
| October 4, 2016 | NCT02922712 | Evaluation of the Efficacy and Safety of Nise 100 mg in the Management of Osteoarthrosis (Gonarthrosis) | Dr. Reddy's Laboratories Limited, India | Phase 4 | Completed | Knee Osteoarthritis | 202 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02922712) |
| October 4, 2016 | NCT02922699 | Efficacy and Saafety of Omez Iin Patients With H.Pylori Associated Diseases | Dr. Reddy's Laboratories Limited, India | Phase 4 | Completed | GERD | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02922699) |
| August 12, 2016 | NCT02865161 | Amtolmetin Gaucil in Knee Osteoarthritis | Dr. Reddy's Laboratories Limited, India | Observational | Completed | Knee Osteoarthritis | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02865161) |
| July 11, 2016 | NCT02828241 | A Study to Assess the Efficacy, Safety and Tolerability of DFD-04 | Dr. Reddy's Laboratories Limited, India | Phase 2 | Completed | Rosacea | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02828241) |
| March 18, 2016 | NCT02712502 | Levofloxacin in Bacterial Rhinosinussitis | Dr. Reddy's Laboratories Limited, India | Observational | Completed | Rhinosinusitis | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02712502) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 184 |
| Phase 1/2 | 2 |
| Phase 2 | 17 |
| Phase 2/3 | 2 |
| Phase 3 | 11 |
| Phase 4 | 5 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 216 |
| Unknown | 5 |
| Terminated | 2 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Fasting | 12 |
| Lecithin Cholesterol Acyltransferase Deficiency | 7 |
| Acne Vulgaris | 4 |
| Arthritis, Rheumatoid | 4 |
| Osteoarthritis, Knee | 3 |
| Migraine Disorders | 2 |
| Surgical Wound Infection | 2 |
| Rosacea | 2 |
| Psoriasis | 2 |
| Lice Infestations | 2 |
| Headache Disorders, Secondary | 1 |
| Urinary Tract Infections | 1 |
| Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| COVID-19 | 1 |
| Hyperlipoproteinemia Type II | 1 |
| Keratosis, Actinic | 1 |
| Acute Pain | 1 |
| Lymphoma, Follicular | 1 |
| Low Back Pain | 1 |
| Pain | 1 |
| Gastroesophageal Reflux | 1 |
| Rhinosinusitis | 1 |
| Arthritis | 1 |
| Joint Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Laboratories in the United States](https://specstream.ai/data/businesses/laboratories/united-states)
- [Electrical supply stores in the United States](https://specstream.ai/data/businesses/electrical-supply-stores/united-states)
- [Hotel supply companies in the United States](https://specstream.ai/data/businesses/hotel-supply-companies/united-states)
- [Nepalese restaurants in the United States](https://specstream.ai/data/businesses/nepalese-restaurants/united-states)
- [Retaining wall suppliers in the United States](https://specstream.ai/data/businesses/retaining-wall-suppliers/united-states)
- [Venezuelan restaurants in the United States](https://specstream.ai/data/businesses/venezuelan-restaurants/united-states)
